Standard Adjuvant Chemotherapy for Triple-Negative Breast Cancer
For stage I triple-negative breast cancer, dose-dense AC (doxorubicin/cyclophosphamide) followed by paclitaxel every 2 weeks or TC (docetaxel/cyclophosphamide) is the standard approach, while for stage II-III disease, neoadjuvant pembrolizumab plus carboplatin/paclitaxel followed by pembrolizumab plus AC/EC, then adjuvant pembrolizumab represents the preferred regimen based on demonstrated overall survival benefit. 1
Stage-Based Treatment Algorithm
Stage I Disease (Adjuvant Setting)
For stage I TNBC, the NCCN recommends these preferred regimens 1:
- Dose-dense AC followed by paclitaxel every 2 weeks (most common approach)
- Dose-dense AC followed by weekly paclitaxel
- TC (docetaxel/cyclophosphamide) - particularly useful when anthracyclines are contraindicated
The St. Gallen consensus supports neoadjuvant therapy when tumors measure ≥2 cm, even in node-negative disease 2. Below this threshold, adjuvant therapy after surgery is appropriate.
Stage II-III Disease (Neoadjuvant-Adjuvant Sequence)
The KEYNOTE-522 regimen is now the Category 1 standard 1:
Neoadjuvant phase:
- Pembrolizumab 200 mg every 3 weeks + carboplatin + paclitaxel (4 cycles)
- Followed by pembrolizumab + cyclophosphamide + doxorubicin or epirubicin (4 cycles)
Surgery
Adjuvant phase:
- Pembrolizumab every 3 weeks for up to 9 cycles
This regimen demonstrated a significant overall survival benefit with 86.6% survival at 60 months versus 81.7% with chemotherapy alone (P=0.002) 3. The pathologic complete response rate was 65% with pembrolizumab versus 51% without 1.
Critical Post-Neoadjuvant Decisions
If Residual Disease After Neoadjuvant Therapy
Adjuvant capecitabine is mandatory for patients with residual disease after completing taxane-, alkylator-, and anthracycline-based neoadjuvant chemotherapy 1. This recommendation is based on the CREATE-X study and real-world data showing:
- Improved recurrence-free survival (HR 0.70,95% CI 0.54-0.91) 4
- Improved distant recurrence-free survival (HR 0.71,95% CI 0.54-0.93) 4
- Improved overall survival (HR 0.66,95% CI 0.49-0.90) 4
Capecitabine should be given for 6-8 cycles following surgery and completion of neoadjuvant therapy.
If Germline BRCA1/2 Mutation Present
Adjuvant olaparib is recommended for patients with germline BRCA1/2 mutations 1. This applies to stages I-III disease. Note that patients in the OlympiA trial did not receive capecitabine, so there are no data on optimal sequencing when both agents are indicated.
Alternative Regimens for Specific Circumstances
Anthracycline-Free Option (Stage II-III)
For patients who cannot receive anthracyclines, docetaxel/carboplatin/pembrolizumab for 6 cycles is listed as useful in certain circumstances 1. However, this should not routinely substitute for KEYNOTE-522, particularly in patients with axillary lymph node metastases, where the anthracycline-containing regimen appears more effective (pCR 65% vs 45% in node-positive disease) 1.
Stage II-III Patients Ineligible for Pembrolizumab
If pembrolizumab is contraindicated, the stage I preferred regimens (dose-dense AC followed by paclitaxel or TC) can be used as alternatives 1. Addition of carboplatin to anthracycline-taxane backbones improves pathologic complete response and long-term outcomes (DFS HR 0.63, OS HR 0.69) 5, though this comes with increased hematological toxicity.
Important Caveats and Pitfalls
Do not use pembrolizumab solely in the adjuvant setting - there is no evidence supporting benefit from checkpoint inhibitors when administered only after surgery without prior neoadjuvant administration 2. The survival benefit requires the neoadjuvant-adjuvant sequence.
Counsel patients about immune-related adverse events with pembrolizumab, particularly permanent endocrinopathies 2. However, surgical outcomes and time to adjuvant therapy are not adversely affected 6.
Do not omit capecitabine in residual disease - real-world data shows only 55.6% of eligible patients receive it 4, representing a significant missed opportunity for improved survival.
Toxicity management is critical - platinum-based regimens increase grade III/IV neutropenia (RR 1.53), anemia (RR 8.20), and thrombocytopenia (RR 7.59), requiring more frequent dose reductions and delays 5. However, febrile neutropenia, renal impairment, and treatment-related death remain rare.